- Home
- IMNM vs HAYW Comparison
IMNM vs HAYW Comparison
Compare IMNM & HAYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | HAYW |
|---|---|---|
| Founded | 2006 | 1925 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMNM | HAYW |
|---|---|---|
| Price | $18.76 | $16.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $35.13 | $17.50 |
| AVG Volume (30 Days) | 1.4M | ★ 4.4M |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | 25.93 |
| EPS | N/A | ★ 0.46 |
| Revenue | $6,941,000.00 | ★ $1,122,155,000.00 |
| Revenue This Year | N/A | $5.81 |
| Revenue Next Year | N/A | $4.97 |
| P/E Ratio | ★ N/A | $36.01 |
| Revenue Growth | N/A | ★ 6.71 |
| 52 Week Low | $16.41 | $11.24 |
| 52 Week High | $30.06 | $17.42 |
Technical Indicators
Market Signals| Indicator | IMNM | HAYW |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 67.19 |
| Support Level | $17.18 | $14.41 |
| Resistance Level | $23.30 | $17.30 |
| Average True Range (ATR) | 1.39 | 0.60 |
| MACD | 0.20 | 0.09 |
| Stochastic Oscillator | 25.98 | 81.88 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2025.